Green Cross Biotherapeutics Inc. (GCBT)

GCBT is the strategic foothold for Green Cross’ business expansion to the North American and European markets. We are building a state of the art bio-manufacturing facility for plasma proteins and will be the only intravenous immunoglobulin (IVIG) and albumin producer in Canada.

More

Product list

Green Cross Biotherapeutics Inc. (GCBT) will initially manufacture two products: Intravenous Immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns.

More

Contact us

For all inquiries about Green Cross Biotherapeutics Inc., Project Oasis, corporate information, customer relations or about any of our products, click “More” to send us a message.

More

Recent News

30Oct

Québec marks the inauguration of the Green Cross Biotherapeutics facilities in Montréal

0 Comments
Montréal, October 30, 2017 – Green Cross Biotherapeutics today inaugurated its new plasma fractionation plant in Technoparc Montréal, a $400-million project that... Read More →
30Oct

Green Cross Biotherapeutics inaugurates its state-of-the-art facility in Montreal

0 Comments
PDF version of the press release. Montreal, Québec (October 30, 2017)—Green Cross Biotherapeutics Inc. (GCBT), a Montreal-based biopharmaceutical company and... Read More →

A Major Project in Canada

Project Oasis

Project Oasis is a plan to expand Green Cross’ business to North America and Europe. Its Montreal plant will be the project`s focal point. $400 million will be invested in Canada’s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.

More

Back to Top